company background image
MACK logo

Merrimack Pharmaceuticals NasdaqGM:MACK Stock Report

Last Price

US$15.13

Market Cap

US$223.7m

7D

0.07%

1Y

21.7%

Updated

21 May, 2024

Data

Company Financials

Merrimack Pharmaceuticals, Inc.

NasdaqGM:MACK Stock Report

Market Cap: US$223.7m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MACK Stock Overview

Operates as a biopharmaceutical company in the United States. More details

MACK fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Merrimack Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Merrimack Pharmaceuticals
Historical stock prices
Current Share PriceUS$15.13
52 Week HighUS$15.89
52 Week LowUS$11.53
Beta1.42
1 Month Change2.79%
3 Month Change3.07%
1 Year Change21.72%
3 Year Change134.21%
5 Year Change140.16%
Change since IPO-74.95%

Recent News & Updates

We're Not Worried About Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn

Feb 14
We're Not Worried About Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn

Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Are In A Position To Invest In Growth

Sep 23
Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Are In A Position To Invest In Growth

Recent updates

We're Not Worried About Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn

Feb 14
We're Not Worried About Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn

Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Are In A Position To Invest In Growth

Sep 23
Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Are In A Position To Invest In Growth

Merrimack Pharmaceuticals GAAP EPS of -$0.04

Aug 04

Here's Why We're Not At All Concerned With Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn Situation

Mar 19
Here's Why We're Not At All Concerned With Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn Situation

We're Interested To See How Merrimack Pharmaceuticals (NASDAQ:MACK) Uses Its Cash Hoard To Grow

May 19
We're Interested To See How Merrimack Pharmaceuticals (NASDAQ:MACK) Uses Its Cash Hoard To Grow

Are Insiders Selling Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Stock?

Feb 22
Are Insiders Selling Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Stock?

Merrimack Pharmaceuticals (NASDAQ:MACK) Is In A Strong Position To Grow Its Business

Jan 01
Merrimack Pharmaceuticals (NASDAQ:MACK) Is In A Strong Position To Grow Its Business

Shareholder Returns

MACKUS BiotechsUS Market
7D0.07%2.7%-1.4%
1Y21.7%-13.0%10.5%

Return vs Industry: MACK exceeded the US Biotechs industry which returned 5.8% over the past year.

Return vs Market: MACK underperformed the US Market which returned 26% over the past year.

Price Volatility

Is MACK's price volatile compared to industry and market?
MACK volatility
MACK Average Weekly Movement0.7%
Biotechs Industry Average Movement12.1%
Market Average Movement8.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market4.1%

Stable Share Price: MACK has not had significant price volatility in the past 3 months.

Volatility Over Time: MACK's weekly volatility (1%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1993n/aGary Crockerwww.merrimack.com

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Merrimack Pharmaceuticals, Inc. Fundamentals Summary

How do Merrimack Pharmaceuticals's earnings and revenue compare to its market cap?
MACK fundamental statistics
Market capUS$223.75m
Earnings (TTM)-US$1.35m
Revenue (TTM)n/a
0.0x
P/S Ratio
-166.2x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MACK income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$1.35m
Earnings-US$1.35m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.091
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did MACK perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/05/21 01:49
End of Day Share Price 2024/05/17 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Merrimack Pharmaceuticals, Inc. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael UlzBaird
Rachel McMinnBofA Global Research
Jonathan AschoffBrean Capital